Halozyme Therapeutics (NASDAQ: HALO) saw its stock surge 6.10% in after-hours trading on Tuesday, following the release of its impressive first-quarter 2025 results and an upward revision of its full-year guidance.

The biotechnology company reported adjusted earnings per share of $1.11 for Q1, significantly beating the analyst consensus estimate of $0.94. This represents a 40.51% increase from the same period last year. Halozyme's quarterly revenue also exceeded expectations, coming in at $264.86 million, a 35.22% year-over-year increase and well above the estimated $230.18 million.

In light of these strong results, Halozyme raised its 2025 financial guidance. The company now expects full-year revenue between $1.2 billion and $1.28 billion, up from its previous forecast. Additionally, Halozyme increased its non-GAAP EPS guidance to a range of $5.30 to $5.70. Further boosting investor confidence, the company announced a new $250 million share repurchase program, signaling management's optimism about Halozyme's future prospects and commitment to enhancing shareholder value.